Related references
Note: Only part of the references are listed.PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy
M. Cecilia Caino et al.
CLINICAL CANCER RESEARCH (2016)
SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets
Jing Guo et al.
NUCLEIC ACIDS RESEARCH (2016)
Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
Hideaki Ogiwara et al.
CANCER DISCOVERY (2016)
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Anna C. Groner et al.
CANCER CELL (2016)
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development
Rui Lu et al.
CANCER CELL (2016)
G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status
Pallavi Agarwal et al.
CANCER LETTERS (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
Dual Chromatin and Cytoskeletal Remodeling by SETD2
In Young Park et al.
CELL (2016)
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng et al.
CLINICAL CANCER RESEARCH (2016)
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
Lorenzo Falchi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses
Andre Kunert et al.
JOURNAL OF IMMUNOLOGY (2016)
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2
Erik Eggert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates
Hazem Ahmed et al.
JOURNAL OF PROTEOME RESEARCH (2016)
Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics
Jonathan B. Olsen et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Rowan E. Miller et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Marco Sciacovelli et al.
NATURE (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
Maia Vinogradova et al.
NATURE CHEMICAL BIOLOGY (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Konstantinos J. Mavrakis et al.
SCIENCE (2016)
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Gregory V. Kryukov et al.
SCIENCE (2016)
The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas
Dong Fang et al.
SCIENCE (2016)
Inhibition of Lysine-Specific Demethylase-1 (LSD1/KDM1A) Promotes the Adipogenic Differentiation of hESCs Through H3K4 Methylation
Yujing Xiong et al.
STEM CELL REVIEWS AND REPORTS (2016)
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
Melissa Carbonneau et al.
NATURE COMMUNICATIONS (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson et al.
NATURE COMMUNICATIONS (2016)
Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis
Cigall Kadoch
CANCER DISCOVERY (2016)
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Hengrui Zhu et al.
CELL REPORTS (2016)
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
Katya Marjon et al.
CELL REPORTS (2016)
Inhibition of Lysine-Specific Demethylase-1 (LSD1/KDM1A) Promotes the Adipogenic Differentiation of hESCs Through H3K4 Methylation
Yujing Xiong et al.
STEM CELL REVIEWS AND REPORTS (2016)
Negative regulation of DNMT3A de novo DNA methylation by frequently overexpressed UHRF family proteins as a mechanism for widespread DNA hypomethylation in cancer
Yuanhui Jia et al.
CELL DISCOVERY (2016)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Sophia X. Pfister et al.
CANCER CELL (2015)
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNFMutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
Bhavatarini Vangamudi et al.
CANCER RESEARCH (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Nicole Stopa et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee et al.
CLINICAL CANCER RESEARCH (2015)
Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma
Oumou Goundiam et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma
Pengfei Zhang et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2015)
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
Hannah Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal et al.
MOLECULES (2015)
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Junwei Shi et al.
NATURE BIOTECHNOLOGY (2015)
What are super-enhancers?
Sebastian Pott et al.
NATURE GENETICS (2015)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Gene essentiality and synthetic lethality in haploid human cells
Vincent A. Blomen et al.
SCIENCE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
The NSD family of protein methyltransferases in human cancer
Theodore Vougiouklakis et al.
EPIGENOMICS (2015)
Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity
Akihiro Fujimoto et al.
NATURE COMMUNICATIONS (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells
Bo Tang et al.
ONCOTARGET (2015)
RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20
Jin Woo Park et al.
SCIENTIFIC REPORTS (2015)
TET proteins and the control of cytosine demethylation in cancer
Laurianne Scourzic et al.
GENOME MEDICINE (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Synthesis of lysine methyltransferase inhibitors
Chunngai Hui et al.
FRONTIERS IN CHEMISTRY (2015)
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia
Joni Van der Meulen et al.
BLOOD (2015)
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
Bowen Xu et al.
BLOOD (2015)
KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review
Young-Won Chin et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia
William N. Pappano et al.
PLOS ONE (2015)
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases
Rajesh C. Rao et al.
NATURE REVIEWS CANCER (2015)
Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS
Valerie Proulle et al.
BLOOD (2014)
Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
Katherine C. Helming et al.
CANCER CELL (2014)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα
Keisuke Yamamoto et al.
CARCINOGENESIS (2014)
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Luke A. Gilbert et al.
CELL (2014)
Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
A. Stathis et al.
EUROPEAN JOURNAL OF CANCER (2014)
KDM4B as a Target for Prostate Cancer: Structural Analysis and Selective Inhibition by a Novel Inhibitor
Chia-Han Chu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein-Protein Interaction
Shihan He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
Boris G. Wilson et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia
Fang Cao et al.
MOLECULAR CELL (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
Pragya Srivastava et al.
LEUKEMIA RESEARCH (2014)
Landscape of genomic alterations in cervical carcinomas
Akinyemi I. Ojesina et al.
NATURE (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma
Carolyn S. Lee et al.
NATURE GENETICS (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Rintaro Hashizume et al.
NATURE MEDICINE (2014)
SET-ting the stage for DNA repair
Deepak K. Jha et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks
Francois Aymard et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
A. R. Grayson et al.
ONCOGENE (2014)
DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy
Wei Liu et al.
PLOS ONE (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
Gregory R. Hoffman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A rationale to target the SWI/SNF complex for cancer therapy
Anja F. Hohmann et al.
TRENDS IN GENETICS (2014)
Histone H3 Mutations in Pediatric Brain Tumors
Xiaoyang Liu et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
Ramzi F. Sweis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes
Wangzhi Li et al.
EPIGENOMICS (2014)
A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice
Chen-Chun Pai et al.
NATURE COMMUNICATIONS (2014)
MAX Inactivation in Small Cell Lung Cancer Disrupts MYC-SWI/SNF Programs and Is Synthetic Lethal with BRG1
Octavio A. Romero et al.
CANCER DISCOVERY (2014)
Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition
Eleftherios P. Samartzis et al.
ONCOTARGET (2014)
SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability
Sophia X. Pfister et al.
CELL REPORTS (2014)
SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint
Silvia Carvalho et al.
ELIFE (2014)
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Kunle Odunsi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The anticancer effects of HDAC inhibitors require the immune system
Alison C. West et al.
ONCOIMMUNOLOGY (2014)
Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas
Adam M. Fontebasso et al.
ACTA NEUROPATHOLOGICA (2013)
Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers
Min S. Kim et al.
APMIS (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Histone H3.3 Mutations: A Variant Path to Cancer
Benjamin T. K. Yuen et al.
CANCER CELL (2013)
Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas
Sebastian Bender et al.
CANCER CELL (2013)
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
Eric Letouze et al.
CANCER CELL (2013)
KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells
William L. Berry et al.
CANCER RESEARCH (2013)
A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
Takahiro Oike et al.
CANCER RESEARCH (2013)
KDM4A Lysine Demethylase Induces Site-Specific Copy Gain and Rereplication of Regions Amplified in Tumors
Joshua C. Black et al.
CELL (2013)
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
A. Ari Hakimi et al.
CLINICAL CANCER RESEARCH (2013)
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
Tianzhu Qiu et al.
FUTURE ONCOLOGY (2013)
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Kui-Ming Chan et al.
GENES & DEVELOPMENT (2013)
Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma
Gilles Manceau et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions
Lisa M. Kopp et al.
MOLECULAR IMMUNOLOGY (2013)
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l
L. Chen et al.
LEUKEMIA (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer
Woojin Kim et al.
NATURE CHEMICAL BIOLOGY (2013)
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
Mark Sausen et al.
NATURE GENETICS (2013)
Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas
Miriam J. Smith et al.
NATURE GENETICS (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover
Kelly Coffey et al.
NUCLEIC ACIDS RESEARCH (2013)
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
A. Hunter Shain et al.
PLOS ONE (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Peter W. Lewis et al.
SCIENCE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Lynn Bjerke et al.
CANCER DISCOVERY (2013)
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Alexandre Puissant et al.
CANCER DISCOVERY (2013)
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines
Sergiy Konovalov et al.
JOURNAL OF OVARIAN RESEARCH (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
Kristian W. Pajtler et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2013)
Linking of 2-Oxoglutarate and Substrate Binding Sites Enables Potent and Highly Selective Inhibition of JmjC Histone Demethylases
Esther C. Y. Woon et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing
Anna Dolnik et al.
BLOOD (2012)
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
William J. Harris et al.
CANCER CELL (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors
Mengtao Xiao et al.
GENES & DEVELOPMENT (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Novel mutations target distinct subgroups of medulloblastoma
Giles Robinson et al.
NATURE (2012)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Jeremy Schwartzentruber et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang et al.
NATURE (2012)
New lysine methyltransferase drug targets in cancer
Tobias Wagner et al.
NATURE BIOTECHNOLOGY (2012)
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes
Matthieu Le Gallo et al.
NATURE GENETICS (2012)
The genetic landscape of mutations in Burkitt lymphoma
Cassandra Love et al.
NATURE GENETICS (2012)
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
Cecile Guichard et al.
NATURE GENETICS (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
TET2 and DNMT3A Mutations in Human T-Cell Lymphoma
Lucile Couronne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
Li Shen et al.
PLOS ONE (2012)
Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer
Tangfeng Lv et al.
PLOS ONE (2012)
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer
A. Hunter Shain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients
Ze-Kun Zhao et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Wenyu Yu et al.
NATURE COMMUNICATIONS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast
Nuran Serce et al.
BMC CLINICAL PATHOLOGY (2012)
The determinants of tumour immunogenicity
Thomas Blankenstein et al.
NATURE REVIEWS CANCER (2012)
SDH mutations in cancer
Chiara Bardella et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2011)
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Damian B. Yap et al.
BLOOD (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
Mahadev Rao et al.
CANCER RESEARCH (2011)
Genetic Interactions in Cancer Progression and Treatment
Alan Ashworth et al.
CELL (2011)
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury et al.
EMBO REPORTS (2011)
Romidepsin: a novel histone deacetylase inhibitor for cancer
Erin M. Bertino et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway
Veerauo V. Konkankit et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
PHF6 mutations in adult acute myeloid leukemia
P. Van Vlierberghe et al.
LEUKEMIA (2011)
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2011)
CREBBP mutations in relapsed acute lymphoblastic leukaemia
Charles G. Mullighan et al.
NATURE (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Ignacio Varela et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
The genomic complexity of primary human prostate cancer
Michael F. Berger et al.
NATURE (2011)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Yaoting Gui et al.
NATURE GENETICS (2011)
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
Kai Wang et al.
NATURE GENETICS (2011)
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma
Meng Li et al.
NATURE GENETICS (2011)
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia
Xiao-Jing Yan et al.
NATURE GENETICS (2011)
Harnessing synthetic lethal interactions in anticancer drug discovery
Denise A. Chan et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma
J. A. Anderton et al.
ONCOGENE (2011)
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining
Sheema Fnu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis
Lei Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
Daniel Antunes Moreno et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
MLL-AF9-Induced Leukemogenesis Requires Coexpression of the Wild-Type Mll Allele
Austin T. Thiel et al.
CANCER CELL (2010)
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Boris G. Wilson et al.
CANCER CELL (2010)
Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma
Gerben Duns et al.
CANCER RESEARCH (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth
Till Milde et al.
CLINICAL CANCER RESEARCH (2010)
Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases
David C. Bedford et al.
EPIGENETICS (2010)
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Jefferson Pessoa Hemerly et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
Heiner Adams et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
O. Kosmider et al.
LEUKEMIA (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh et al.
NATURE (2010)
TRIM24 links a non-canonical histone signature to breast cancer
Wen-Wei Tsai et al.
NATURE (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
K. E. Yen et al.
ONCOGENE (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors
Shohei Hamada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab et al.
BLOOD (2009)
The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters
W. Al Sarakbi et al.
BMC CANCER (2009)
Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex
Xi Wang et al.
CANCER RESEARCH (2009)
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma
Shuhei Komatsu et al.
CARCINOGENESIS (2009)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Ina Oehme et al.
CLINICAL CANCER RESEARCH (2009)
Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas
Portia A. Kreiger et al.
MODERN PATHOLOGY (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M. C. Langemeijer et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Small Cell Undifferentiated Variant of Hepatoblastoma: Adverse Clinical and Molecular Features Similar to Rhabdoid Tumors
Angela D. Trobaugh-Lotrario et al.
PEDIATRIC BLOOD & CANCER (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
Florian R. Fritzsche et al.
BMC CANCER (2008)
Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors
Markus Heidenblad et al.
BMC MEDICAL GENOMICS (2008)
An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1
Christin L. Hanigan et al.
GASTROENTEROLOGY (2008)
Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor
P. V. Pena et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus
Sima Kheradmand Kia et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast
Assen Roguev et al.
SCIENCE (2008)
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells
C. A. French et al.
ONCOGENE (2008)
Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice
G. Howard et al.
ONCOGENE (2008)
Epigenetic control of the immune escape mechanisms in malignant carcinomas
A. Francesca Setiadi et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
MLL translocations, histone modifications and leukaemia stem-cell development
Andrei V. Krivtsov et al.
NATURE REVIEWS CANCER (2007)
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy
S. Glaros et al.
ONCOGENE (2007)
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response
Chiara Gorrini et al.
NATURE (2007)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint
Daniel Stauffer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Epigenetic regulation of immune escape genes in cancer
Thomas B. Tomasi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy
Adam R. Karpf
EPIGENETICS (2006)
Identification of NUP98 abnormalities in acute leukemia:: JARID1A (12p13) as a new partner gene
LJCM van Zutven et al.
GENES CHROMOSOMES & CANCER (2006)
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
S Ropero et al.
NATURE GENETICS (2006)
Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement
LY Shih et al.
LEUKEMIA (2006)
Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development
LH Kasper et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells
Wu Xu et al.
BLOOD (2006)
Epigenetic therapy of cancer: past, present and future
CB Yoo et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin
T Hirota et al.
NATURE (2005)
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B
S Skov et al.
CANCER RESEARCH (2005)
Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells
SD Chou et al.
INTERNATIONAL IMMUNOLOGY (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes
ZJ Yan et al.
GENES & DEVELOPMENT (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases
B Brueckner et al.
CANCER RESEARCH (2005)
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas
P Modena et al.
CANCER RESEARCH (2005)
hDOT1L links histone methylation to leukemogenesis
Y Okada et al.
CELL (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Up-regulation of DNA methyltransferase 3B expression in endometrial cancers
F Jin et al.
GYNECOLOGIC ONCOLOGY (2005)
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma
J Yu et al.
BMC CANCER (2004)
An epigenetically altered tumor cell vaccine
ANH Khan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Epigenetic targets for immune intervention in human malignancies
M Maio et al.
ONCOGENE (2003)
Regulation of distinct biological activities of the NF-κB transcription factor complex by acetylation
LF Chen et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2003)
Induction of tumors in mice by genomic hypomethylation
F Gaudet et al.
SCIENCE (2003)
Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers
Y Kanai et al.
CANCER LETTERS (2003)
Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5
CWM Roberts et al.
CANCER CELL (2002)
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
I Rhee et al.
NATURE (2002)
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
IPM Tomlinson et al.
NATURE GENETICS (2002)
BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)
CA French et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Expression of HLA class I antigens and restoration of antigen-specific ctl response in melanoma cells following 5-aza-2′-deoxycytidine treatment
A Serrano et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins
PM Ayton et al.
ONCOGENE (2001)
Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia
S Mizuno et al.
BLOOD (2001)
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
WJ Magner et al.
JOURNAL OF IMMUNOLOGY (2000)
Regulation of chromatin structure by site-specific histone H3 methyltransferases
S Rea et al.
NATURE (2000)
DNA hypermethylation in tumorigenesis - epigenetics joins genetics
SB Baylin et al.
TRENDS IN GENETICS (2000)
Share Paper
